W. K. Hong

4.1k total citations · 1 hit paper
42 papers, 3.1k citations indexed

About

W. K. Hong is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, W. K. Hong has authored 42 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 10 papers in Otorhinolaryngology. Recurrent topics in W. K. Hong's work include Lung Cancer Treatments and Mutations (15 papers), Head and Neck Cancer Studies (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). W. K. Hong is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Head and Neck Cancer Studies (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). W. K. Hong collaborates with scholars based in United States, Switzerland and China. W. K. Hong's co-authors include Isaiah W. Dimery, Scott M. Lippman, J. S. Lee, Jack A. Roth, Frank V. Fossella, E. Neely Atkinson, R. Komaki, Martin Chasen, Malcolm H. McGavran and Joe B. Putnam and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

W. K. Hong

41 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer

1994 804 citations Jack A. Roth, Frank V. Fossella et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by W. K. Hong

Since Specialization

Citations

This map shows the geographic impact of W. K. Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. K. Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. K. Hong more than expected).

Fields of papers citing papers by W. K. Hong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. K. Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. K. Hong. The network helps show where W. K. Hong may publish in the future.

Co-authorship network of co-authors of W. K. Hong

This figure shows the co-authorship network connecting the top 25 collaborators of W. K. Hong. A scholar is included among the top collaborators of W. K. Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. K. Hong. W. K. Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Subthreshold anxiety in Chinese college students: prevalence, gender differences, and correlates 2025 ·BMC Psychology ·Xu Han, Siqi Zhao, Pu Ge, Y. Liu, Qiyu Li, (unknown), (unknown), L.-Z. Pan, (unknown), W. K. Hong, (unknown), Jia‐Yi Lin, Yibo Wu	1
2	Prevalence and associated factors influencing the use of antibiotics for self-medication among Chinese residents: a cross-sectional study in 2021 2025 ·Archives of Public Health ·Danni Wang, Pu Ge, Dongying Xue, Chen Hu, Guoyou Huang, Jiale Qi, W. K. Hong, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ying Bian, Yibo Wu	0
3	Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. 2010 ·Journal of Clinical Oncology ·(unknown), Ignacio I. Wistuba, Reza J. Mehran, Justyna Gil, (unknown), (unknown), (unknown), S. M. Lippman, W. K. Hong	8
4	Biologic risk model development for recurrent and second primary tumors (SPTs) in patients (pts) with early stage non-small cell lung cancer (ES NSCLC). 2010 ·Journal of Clinical Oncology ·Kathryn A. Gold, (unknown), (unknown), Carmen Behrens, (unknown), (unknown), (unknown), (unknown), Ignacio I. Wistuba, W. K. Hong	1
5	A Risk Model for Prediction of Lung Cancer 2007 ·JNCI Journal of the National Cancer Institute ·M R Spitz, W. K. Hong, Christopher I. Amos, Xifeng Wu, Matthew B. Schabath, Qian Dong, Sanjay Shete, Carol J. Etzel	302
6	Proliferative Changes in the Bronchial Epithelium of Former Smokers Treated With Retinoids 2007 ·JNCI Journal of the National Cancer Institute ·Walter N. Hittelman, D. D. Liu, Jonathan M. Kurie, R. Lotan, J. S. Lee, Fadlo R. Khuri, Heladio P. Ibarguen, Rodolfo C. Morice, G. Walsh, Jack A. Roth, John D. Minna, Jae Y. Ro, A. Broxson, W. K. Hong, J. Jack Lee	14
7	Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) 2005 ·Journal of Clinical Oncology ·E. S. Kim, M.S. Kies, Anita L. Sabichi, Lawrence Ginsberg, Brian J. Burke, F. Christopher Holsinger, Lei Feng, Mylene T. Truong, Bonnie S. Glisson, W. K. Hong	13
8	A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) 2004 ·Journal of Clinical Oncology ·(unknown), Ronald Herbst, Coleman K. Obasaju, Frank V. Fossella, V. Papadimitrakopoulou, K. M. W. Pisters, George Blumenschein, (unknown), W. K. Hong, Ralph Zinner	16
9	Retinoic Acid Receptor and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers 2003 ·JNCI Journal of the National Cancer Institute ·Jean‐Charles Soria, Xiaochun Xu, D. D. Liu, J. Jack Lee, Jonathan M. Kurie, (unknown), Fadlo R. Khuri, Mao Li, W. K. Hong, R. Lotan	16
10	Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer 2001 ·JNCI Journal of the National Cancer Institute ·Scott M. Lippman, J. Jack Lee, Daniel D. Karp, Everett E. Vokes, Steven E. Benner, Gary E. Goodman, Fadlo R. Khuri, Randolph S. Marks, R Winn, (unknown), S. L. Graziano, David R. Gandara, Gordon Okawara, (unknown), Betsy Williams, Carlos A. Pérez, (unknown), R. Lotan, Jack A. Roth, W. K. Hong	213
11	Phenotype and Genotype of Advanced Premalignant Head and Neck Lesions After Chemopreventive Therapy 1998 ·JNCI Journal of the National Cancer Institute ·Li Mao, V. Papadimitrakopoulou, Dong M. Shin, You-Hong Fan, Xiaogen Zhou, J. S. Lee, W. K. Hong, A. K. El-Naggar, Hee‐Chul Shin, Gary L. Clayman, J. Jack Lee, WN Hittelman, S. M. Lippman	122
12	Suppression of Retinoic Acid Receptor in Non-Small-Cell Lung Cancer In Vivo: Implications for Lung Cancer Development 1997 ·JNCI Journal of the National Cancer Institute ·Xiaochun Xu, Gabriella Sozzi, (unknown), J. Jack Lee, Ugo Pastorino, S. Pilotti, Jonathan M. Kurie, W. K. Hong, R. Lotan	178
13	Gene replacement for lung cancer 1997 ·Lung Cancer ·Jack A. Roth, S.G. Swisher, David Lawrence, B L Kemp, C. Humberto Carrasco, A. K. El-Naggar, (unknown), B.S. Glisson, W. K. Hong, Fadlo R. Khuri, Jonathan M. Kurie, Jonathan C. Nesbitt, Katherine M.W. Pisters, Joe B. Putnam, David S. Schrump, (unknown), (unknown)	1
14	Mutagen Sensitivity as a Risk Factor for Second Malignant Tumors Following Malignancies of the Upper Aerodigestive Tract 1994 ·JNCI Journal of the National Cancer Institute ·M R Spitz, Ashraful Hoque, Zoltán Trizna, Stimson P. Schantz, Christopher I. Amos, Terri M. King, Melissa L. Bondy, W. K. Hong, Tsai‐Ching Hsu	94
15	A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer breakdown → 1994 ·JNCI Journal of the National Cancer Institute ·Jack A. Roth, Frank V. Fossella, R. Komaki, Michael Ryan, Joe B. Putnam, J. S. Lee, Hari M. Dhingra, (unknown), Martin Chasen, Malcolm H. McGavran, E. Neely Atkinson, W. K. Hong	804
16	Detection of Chromosomal Polysomy in Oral Leukoplakia, a Premalignant Lesion 1993 ·JNCI Journal of the National Cancer Institute ·Jack Lee, Scott Y. H. Kim, W. K. Hong, Scott M. Lippman, J Y Ro, (unknown), Walter N. Hittelman	48
17	Overview of Combined Modality Therapies for Head and Neck Cancer 1993 ·JNCI Journal of the National Cancer Institute ·Isaiah W. Dimery, W. K. Hong	178
18	13-cis-Retinoic Acid Plus Interferon- 2a in Locally Advanced Squamous Cell Carcinoma of the Cervix 1993 ·JNCI Journal of the National Cancer Institute ·S. M. Lippman, J. J. Kavanagh, M. Paredes-Espinoza, (unknown), Patricia Paredes-Casillas, W. K. Hong, Giorgio Massimini, (unknown), I. H. Krakoff	76
19	13-cis-Retinoic Acid and Interferon -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin 1992 ·JNCI Journal of the National Cancer Institute ·S. M. Lippman, David Parkinson, Loretta M. Itri, Randal S. Weber, Stimson P. Schantz, David M. Ota, Mark A. Schusterman, I. H. Krakoff, Jordan U. Gutterman, W. K. Hong	305
20	Biomarkers as Intermediate End Points in Chemoprevention Trials 1990 ·JNCI Journal of the National Cancer Institute ·Scott M. Lippman, (unknown), Reuben Lotan, WN Hittelman, Michael J. Wargovich, W. K. Hong	149

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact